Overexpression of dopamine receptor D2 promotes colorectal cancer progression by activating the β-catenin/ZEB1 axis

Hyunjung Lee1 | Sehwan Shim1 | Joon Seog Kong1,2 | Min-Jung Kim1 | Sunhoo Park1,2 | Seung-Sook Lee1,2 | Areumnuri Kim1

1Laboratory of Radiation Exposure & Therapeutics, National Radiation Emergency Medical Center, Seoul, Korea
2Department of Pathology, Korea Cancer Center Hospital, Korea Institute of Radiological & Medical Science, Seoul, Korea

Correspondence
Areumnuri Kim, Ph.D., Laboratory of Radiation Exposure & Therapeutics, Korea Institute of Radiological & Medical Science, 215-4 Gongneung-dong, Nowon-ku, 139-706, Seoul, Korea. Email: nurikim@kirams.re.kr

Funding information
This study was supported by a grant from the Korea Institute of Radiological and Medical Sciences (KIRAMS), funded by the Ministry of Science and ICT (MSIT), Republic of Korea. (Grant Nos. 50551-2020; 50535-2020).

Abstract
Colorectal cancer (CRC) is a recurring cancer that is often resistant to conventional therapies and therefore requires the development of molecular-based therapeutic approaches. Dopamine receptor D2 (DRD2) is associated with the growth of many types of tumors, but its oncogenic role in CRC is unclear. Here, we observed that elevated DRD2 expression was associated with a poor survival rate among patients with CRC. Depletion of DRD2 suppressed CRC cell growth and motility by downregulating β-catenin/ZEB signaling in vitro and in vivo, whereas overexpression of DRD2 promoted CRC cell progression. Inhibition of DRD2 by the antagonist pimozide inhibited tumor growth and lymph node metastasis in vivo and enhanced the cytotoxic effects of conventional agents in vitro. Taken together, our findings indicate that targeting the DRD2/β-catenin/ZEB1 signaling axis is a potentially promising therapeutic strategy for patients with CRC.

KEYWORDS
colorectal cancer, DRD2, metastasis, pimozide, ZEB1

INTRODUCTION

Colorectal cancer (CRC) is the third most commonly diagnosed malignancy, with high mortality worldwide.1 Many studies have sought to uncover the mechanisms of CRC growth and metastasis in an effort to identify new molecular targets.2–5 However, although targeted therapies for CRC have shown improved therapeutic efficacy, they do not significantly increase the survival rate.6 Therefore, approaches targeting deeper molecular mechanisms are required to overcome resistance of the clinical response to CRC therapy. G protein-coupled receptors (GPCRs) are large and diverse signaling receptors that are altered in various cancers and regulate cancer progression. Dopamine receptors (DRs), a class of GPCRs, have 5 subtypes named DRD1–DRD5. Elevated levels of DRs are associated with tumor growth and prognosis.7 Recent studies have reported that each DR subtype has different functions depending on tumor type. In glioblastoma, inhibition of DRD4 by antagonists selectively suppressed cancer stem cell growth.8 Inhibition of DRD3 signaling is also strongly linked to activation of dendritic cells, which enhance anti-tumor immunity.9 DRD1 is primarily expressed in breast cancer,10 whereas DRD5 is expressed more highly than DRD1 in hepatoma cells.11 Taken together, these studies show that DR overexpression enhances tumor growth and development, suggesting that targeting DRs may be an effective therapeutic strategy for tumors. However, the oncogenic function of DRs and DR-mediated molecular signaling in CRC remains unclear.

The GPCRs and GPCR-associated scaffolding proteins play roles in cancer progression via various downstream signaling pathways, including MAPK/ERK, PI3K/AKT, Wnt/β-catenin, and NF-κB.12 Among these, Wnt/β-catenin signaling is altered in more than 94% of patients with CRC.13 β-Catenin is a key regulator of Wnt signaling,
which is normally targeted for degradation by Axin destruction com-
plex, consisting of adenomatous polyposis coli (APC), casein kinase 1
(CK1), glycogen synthase kinase 3β (GSK-3β), and tightly controls β-
catenin via phosphorylation-mediated proteolysis. Activating mu-
tation in the β-catenin was approximately observed in 1% of patients
with CRC, and high levels of β-catenin in the nucleus are associated
with a poor prognosis in CRC.15,16

Activated β-catenin regulates various target genes, which pro-
mote CRC stem cell self-renewal, tumorigenesis, and chemoresis-
tance.17 Moreover, aberrant Wnt/β-catenin signaling enhances can-
cer cell epithelial-to-mesenchymal transition (EMT), which en-
ables cancer cells to metastasize.18 The EMT phenotype is character-
ized by loss of E-cadherin and upregulation of vimentin and α-smooth
muscle actin.19 Several EMT transcription factors, such as Snail,
Twist-related protein (Twist), Slug, and Zinc Finger E-Box Binding
Homeobox 1 (ZEB1), are involved in enhancing tumor malignancy in
various cancers.20-23 Therefore, inhibition of Wnt/β-catenin signaling
by antagonist and in combination with chemotherapy agents are un-
derway in several clinical studies (https://clinicaltrials.gov/).

In this study, we demonstrate that DRD2 plays an important role
in CRC progression, leading to enhanced cell proliferation, and
migratory and invasive capacities. In addition, we showed that inhibi-
tion of DRD2 by an antagonist suppressed tumor growth and the
metastatic ability of CRC in vitro and in vivo. These findings indicate
that targeting DRD2 is a potentially promising therapeutic approach
for patients with CRC.

2 | MATERIALS AND METHODS

2.1 | Cell culture and reagents

Human colon cancer cell lines HCT116, DLD1, LoVo, HT29, SW620,
and SW480; human rectal cancer cell line SW1463; and human nor-
mal colon epithelial cell line CCD841 were obtained from the ATCC
(Manassas, VA, USA). These cell lines were maintained in RPMI 1640
medium (Lonza, Walkersville, MD, USA) containing 10% fetal bovine
serum (Gibco, Waltham, MA, USA), Penicillin/streptomycin (1%; Gibco)
was added to all culture media. Pimozide, Fluorouracil (5FU), and oxali-
platin were purchased from Sigma-Aldrich (St. Louis, MO, USA).

2.2 | Patient samples

Human tissue microarray slides containing 76 pairs of CRC tissue
and the corresponding non-tumor tissue were purchased from ISU
ABXIS (Seoul, Korea) and 85 CRC tissues were obtained from Biomax
(Derwood, MD, USA). Five patient-derived tumor and normal sam-
ples for quantitative real-time PCR (qPCR) and 3 patient-derived
tumor and normal samples for western blotting were obtained from the
Korea Institute of Radiological and Medical Sciences (Seoul, Korea).
Patient studies were performed using protocols approved by KIRAMS
(K-1702-002-002). All procedures performed with human
participants or animals were in accordance with the ethical stand-
ards of the institutional and/or national research committee.

2.3 | RNA interference and plasmid transfection

To deplete DRD2, lentiviral short hairpin RNA (shRNA) targeting
DRD2 (TRCN 0000350540; CCCGGACACTTCCTTCCGGACTCAAT
ACTCGAGATTTGAGTCCGAAG AG GAGGTGTTCG TRCN 0000
315421; CCGGCACACCTCAACATTGAGTTCTCG AGAACTCAATG
TTGAAGGTTGTTTTTG) and control vectors (shCont) were obtained
from Sigma-Aldrich. Viral particles were incubated with HCT116 and
DLD1 cells for 48 h and selected with puromycin (2 μg/mL). SW480
cells were transfected with a control vector (pcDNA3.1) or plasmid GFP-
tagged DRD2 (pEGFP-DRD2, addgene plasmid #24099; Watertown,
MA, USA) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) for
48 h. Small interfering RNA (siRNA) targeting β-catenin was purchased
from Dharmaco (Lafayette, CO, USA).

2.4 | Cell cycle analysis

HCT116 cells (1 × 105) were treated 10 μmol/L pimozide, 50 μmol/L 5FU
and 50 μmol/L oxaliplatin alone or combined. Cells were fixed in
70% ethanol and treated with 0.1 mg/mL of RNase A (Sigma-Aldrich).
The cells were stained with 50 μg/mL of propidium iodide (EMD
Millipore) and DNA content of cells was analyzed by FACSCanto II
flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA).

2.5 | Cell migration and invasion assay

Cell migration and invasion were analyzed in a 24-well transwell
chamber (Corning, NY, USA) with 8.0-μm pore polycarbonate
membrane-coated inserts. For the invasion assay, cells (2 × 104)
were seeded in the upper compartment of the chamber coated
with Matrigel (BD Biosciences). For the migration assay, cells were
seeded in the chamber in serum-free medium, and RPMI 1640 sup-
plemented with 10% fetal bovine serum was added to the lower
compartment. After incubation at 37°C for 24 h, cells were fixed
in 4% paraformaldehyde, stained with 0.1% crystal violet, and im-
aged under a bright-field microscope (Olympus, Shinjuku, Japan).
Samples were tested in at least triplicate. Data are shown as mean ± standard deviation (SD).

2.6 | Cell proliferation assay

HCT116 cells (3 × 103/well) and DLD1 cells (3 × 103/well) were
plated on a 96-well plate. Cell proliferation was measured using a
cell counting kit (CCK-8; Dojindo) in accordance with the manufac-
turer’s instructions. Data are shown as mean ± SD for 3 independent
experiments.
2.7 | qPCR analysis

Total RNA was isolated from cells using TRIzol® reagent (Invitrogen) following the manufacturer’s protocol. cDNA was synthesized using AccuPower® RT-PreMix (Bioneer, Daejeon, Korea). Gene amplification was carried out using cDNA samples with SYBR® Green-based qPCR. All qPCR amplification analysis was conducted using the SensiFAST™ SYBR® No-ROX One-step kit (Bioline, London, UK) in a LightCycler® 96 (Roche, Basel, Switzerland). qPCR was performed with the following primers:

- DRD1 (Millipore, St. Louis, MO, USA), ZEB1 (Abcam), E-cadherin and β-catenin (BD Biosciences), p-β-catenin (Ser 675), p-β-catenin (Ser 552), p-AKT (Ser 473), AKT, p-GSK3β (Ser 9), (Sensifast and Integrated DNA Technologies, Coralville, IA, USA).

Expression levels of these genes were normalized to that of GAPDH.

2.8 | Immunoblotting analysis

Cells were lysed with NP40 lysis buffer (Pierce, Rockford, IL, USA) containing 1 mM sodium orthovanadate, pH 7.4, and centrifuged at 12 000 rpm for 15 min. Equal amounts (30-100 µg) of protein were separated by SDS-PAGE and then transferred to PVDF membranes. Primary antibodies were purchased against the following proteins: DRD2 (Millipore, St. Louis, MO, USA), ZEB1 (Abcam), E-cadherin and β-catenin (BD Biosciences), p-β-catenin (Ser 675), p-β-catenin (Ser 552), p-AKT (Ser 473), AKT, p-GSK3β (Ser 9), (Sensifast and Integrated DNA Technologies, Coralville, IA, USA), and β-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Membranes were incubated with secondary antibodies for 2 h. Immunopositive bands were visualized using a detection reagent (Thermo Fisher Scientific).

2.9 | Immunohistochemical staining

Tissue samples were fixed in formalin and embedded in paraffin. To remove endogenous peroxidase activity, slides were incubated for 30 min in methanol containing 0.3% H2O2. Antigen retrieval was performed with citrate buffer in a steamer for 30 min. After blocking in 2% bovine serum albumin for 1 h, coverslips were incubated with primary antibodies. Staining was completed with Alexa Fluor 488- or Alexa Fluor 594-conjugated secondary antibody (Invitrogen) for 2 h. Nuclei were counterstained with DAPI (0.2 µg/mL; Sigma-Aldrich) for 10 min. Images of immunostained slides were captured using a microscope (Leica, Bannockburn, IL).

2.10 | Immunofluorescence staining

Cells were fixed in 95% ethyl alcohol and incubated with H2O2 for 30 min. After blocking in 2% bovine serum albumin for 1 h, coverslips were incubated with primary antibodies. Staining was completed with Alexa Fluor 488- or Alexa Fluor 594-conjugated secondary antibody (Invitrogen) for 2 h. Nuclei were counterstained with DAPI (0.2 µg/mL; Sigma-Aldrich) for 10 min. Images of immunostained slides were captured using a microscope (Leica, Bannockburn, IL).

2.11 | In vivo studies

Five-wk-old female BALB/c nude mice were obtained and maintained for 7 d. To examine tumorigenesis, nude mice were injected subcutaneously with shCont-HCT116 (1 × 10^7) and shDRD2-HCT116 (1 × 10^7) (n = 5). Tumor size was measured twice a week with calipers. At 20 d after injection, mice were sacrificed and tumors were isolated for IHC and H&E staining. To observe metastatic potential following DRD2 depletion, HCT116 cells (1 × 10^7) were injected into the spleens of mice. At 3 wk after cell injection, mice were sacrificed, and their liver and lymph nodes were isolated for IHC and H&E staining. To investigate the anti-tumor effects of pimozide, 1 × 10^7 HCT116 cells were injected subcutaneously. At 7 d after implantation, mice were randomly divided into 2 groups. Pimozide was dissolved in dimethyl sulfoxide and diluted in saline. Mice were injected intraperitoneally with 25 mg/kg pimozide or vehicle twice weekly for 18 d. All animal studies were performed using protocols approved by KIRAMS (No. 2020-0032).

2.12 | The Cancer Genome Atlas (TCGA) analysis

To validate the role of DRD2 in CRC, we analyzed TCGA project database (https://tcga-data.nci.nih.gov/tcga/), which contains data from more than 500 patients with CRC, including gene expression data and follow-up information. Data from 597 patients with CRC with DRD2 expression were included in this study. Patients were divided into 2 groups depending on their DRD2 expression level.

2.13 | Statistical analysis

Data are shown as mean ± SD. Differences between groups were determined by one-way ANOVA and Student t tests as appropriate using GraphPad Pro software (GraphPad, San Diego, CA, USA). Values of P < .05 were considered statistically significant.

3 | RESULTS

3.1 | DRD2 overexpression is associated with poor prognosis in patients with CRC

Altered expression of DRs is reported in various cancers and is associated with tumor growth and survival.24 We first investigated mRNA levels of the DR family, including D1, D2, D3, D4, and D5, in human CRC tumor and adjacent non-tumor tissue using qPCR analysis. Among the 5 DRs, expression of DRD2 was the highest in CRC tissue (Figure S1). In addition, western blotting revealed that
DRD2 protein level was elevated in CRC tissue compared with non-tumor tissue (Figure 1A). Next, to determine whether DRD2 expression was associated with clinicopathological features, we analyzed DRD2 expression using a commercially available tissue microarray to evaluate 85 tumor tissue samples. DRD2 expression was significantly correlated with TNM stage, but no significant associations were found between DRD2 expression and age, gender, or differentiation in patients with CRC (Table 1). Moreover, we evaluated survival rate according to DRD2 expression using data from TCGA database. Patients with CRC with high DRD2 expression had markedly worse outcomes than those with low expression (Kaplan-Meier method, Figure 1B). To evaluate the significance of DRD2 expression in patients with CRC, DRD2 expression levels were analyzed by IHC using a commercially tissue microarray to evaluate 76 pairs of tumor tissue and non-tumor samples from patients with CRC. As shown in Figure 1C, the levels of DRD2 expression were associated with CRC development and progression. These results indicated that DRD2 expression may predict the clinical outcomes of CRC, implying that DRD2 is related to the capacity for CRC growth and metastasis.

3.2 Increased DRD2 expression enhances CRC growth in vitro and in vivo

Because elevated DRD2 was associated with poor prognosis of patients with CRC, we investigated the mechanism by which DRD2 increases cancer progression in CRC cells. We examined DRD2 expression levels in 7 human CRC cell lines—SW480, SW620, HCT116, DLD1, SW1463, HT29, and T84—and a normal colon epithelial cell line CCD841 using western blotting. DRD2 was aberrantly expressed in all CRC cell lines compared with the normal cell line (Figure 2A). In particular, DRD2 was expressed more highly in HCT116 and DLD1 cells than in the other CRC cell lines. Therefore, we selected HCT116 and DLD1 cells to further investigate whether increased DRD2 expression affected CRC growth and motility. To test the effect of altered DRD2 expression on CRC growth, we established stable DRD2-depleted HCT116 and DLD1 cell lines using an shRNA system (Figure 2B). Both DRD2-depleted cell lines had significantly decreased colony formation and clonogenicity compared with their control cells (Figure 2C). In addition, depleted DRD2 led to an increase in the apoptotic cells in the sub-G1 fraction and cleaved poly(ADP-ribose)polymerase (PARP) (Figure S3). To determine whether DRD2

| Variable | DRD2 (n, %) | P-value |
|----------|------------|---------|
| Age      |            |         |
| ≥65 y    | 11 (12.9%) | 9 (10.6%) | .47   |
| <65 y    | 32 (37.6%) | 33 (38.8%) |
| Gender   |            |         |
| Female   | 14 (16.5%) | 15 (17.6%) | .50   |
| Male     | 28 (32.4%) | 29 (33.5%) |
| TNM stage|            |         |
| 1A-2B    | 30 (35.2%) | 20 (24.1%) | .05*  |
| 3A-3B    | 13 (15.3%) | 22 (25.9%) |

*P < .05.
contributed to tumor growth in vivo, we subcutaneously injected shCont or shDRD2. Consistent with our in vitro data, tumor growth was suppressed in mice 20 d after injection with DRD2-depleted cells (Figure 2D). We also investigated whether overexpression of DRD2 promoted CRC growth and proliferation by transfecting SW480 cells expressing a low level of DRD2 with the expression vector EGFP-DRD2. Colony-forming ability increased by more than 1.5-fold in DRD2-overexpressing cells compared with the control (Figure 2E). Overexpression of DRD2 decreased also in apoptotic cells (Figure S3). These results indicated that DRD2 accelerates CRC growth and tumorigenicity in vitro and in vivo.

### 3.3 | Overexpression of DRD2 increases the migratory and invasive capacity of CRC cells in vitro and in vivo

We assessed the motility of DRD2-depleted HCT116 and DLD1 cells using a transwell assay. DRD2-depleted cells showed significantly decreased (>50% reduction) migration and invasion compared with control cells (Figure 3A). In addition, we confirmed that adherent junction E-cadherin expression was increased in tumors derived from shDRD2 cells compared with shCont cells, whereas expression of the mesenchymal marker vimentin was reduced in tumors from shDRD2-bearing mice (Figure 3B). Next, to determine whether knockdown of DRD2 blocks cell movement in vivo, we used a spleen-to-liver model. We implanted shCont- and shDRD2-bearing cells into the spleens of mice to test the metastatic ability of CRC. shCont-bearing mice showed more than 20 metastatic liver nodules, whereas shDRD2-bearing mice showed no metastatic nodules (Figure 3C). H&E staining confirmed that DRD2-depleted cells markedly inhibited tumor spread to the liver compared with non-DRD2-depleted shCont cells. In addition, staining of lymph nodes with an antibody to the epithelial marker pan-cytokeratin showed that DRD2-depleted cells attenuated lymphatic metastasis. In contrast with the effect of depleting DRD2, DRD2 overexpression increased the migratory and invasive ability of SW480 cells by ~50% compared with cells transfected with control vector pcDNA3.1 (Figure 3D). These findings suggested that DRD2 expression is a key regulator of metastatic capacity in CRC.
FIGURE 3  DRD2 overexpression accelerates EMT progression in CRC. A, Migratory and invasive ability of shCont- or shDRD2- HCT116 and DLD1 cells was evaluated by crystal violet staining. Graphs indicate relative cell number. Scale bar, 100 μm. B, Expression levels of E-cadherin and vimentin were detected by IHC staining in tumors derived from shCont or shDRD2 cells. Scale bar, 100 μm. Data shown are representative of 3 independent experiments. C, shCont or shDRD2 cells (n = 6/group) were injected into the spleens of nude mice to generate a liver metastasis model. Representative photographs indicate tumor colonization in liver tissue (arrowheads), and the graph indicates the number of tumor nodules (left panel). Representative micrographs of microscopic liver tumors stained with H&E (middle panel). Lymph node metastasis was measured. IHC staining of pan-cytokeratin-positive tumor cells in lymph nodes (right panel). Scale bar, 500 μm (upper) and 100 μm (lower). D, Cell migration and invasion were analyzed in pcDNA3.1 or pEGFP-DRD2 transfected SW480 cells. Scale bar, 100 μm. ***P < .005, **P < .01, and *P < .05
3.4 | DRD2 regulates EMT transcription through the transcription factor ZEB1

As immunofluorescence staining showed that vimentin expression was greatly reduced in DRD2-depleted cells compared with control cells (Figure 4A), we hypothesized that DRD2 regulates metastasis of CRC via changes in transcriptional EMT-related genes. We evaluated the expression levels of EMT-activating transcription factors TWIST, SNAIL, SLUG, ZEB1, BMI1, and EZH2 using qPCR. Among them, ZEB1 was strongly downregulated in DRD2-depleted HCT 116 and DLD1 cells compared with their control cells (Figure 4B). Because β-catenin leads to EMT transition,25 we examined β-catenin, ZEB1, vimentin, and E-cadherin expression levels in DRD2-depleted cells. Expression levels of DRD2, ZEB1, β-catenin, and vimentin expression were decreased in DRD2-depleted cells, whereas E-cadherin expression was increased (Figure 4C). Immunofluorescence staining revealed that expression of both ZEB1 and β-catenin was suppressed by depletion of DRD2 (Figure 4D). In addition, overexpression of DRD2 greatly increased ZEB1 and β-catenin expression in SW480 cells (Figure 4E). Furthermore, IHC staining of human CRC tissue samples showed that DRD2 expression was positively correlated with ZEB1, β-catenin, and vimentin expression (Figure 4F). Collectively, these results showed that elevated DRD2 enhances the migration and invasion of CRC by regulating the β-catenin/ZEB1 pathway.

3.5 | DRD2 modulates the β-catenin/ZEB1 axis in CRC cells

To determine whether DRD2 promotes CRC cell motility through β-catenin, we transiently depleted β-catenin using 2 different sequences of siRNA in SW480 cells overexpressing DRD2. Both forms of siβ-catenin diminished ZEB1 mRNA and protein levels compared with siCont in DRD2-overexpressing SW480 cells (Figure 5A,B). Moreover, downregulation of β-catenin attenuated the migratory
and invasive abilities of DRD2-overexpressing cells (Figure 5C). We also investigated whether DRD2 regulates the β-catenin pathway depending on DRD2 expression. Inhibition of DRD2 in HCT116 cells decreased β-arrestin1/2 and its associated downstream proteins, including β-catenin phosphorylation sites at Ser552 and Ser675, AKT, and activated GSK3β. In addition, these proteins were increased in DRD2-overexpressing SW480 cells (Figure 5D). Next, to determine whether ZEB1 is involved with DRD2-mediated cell motility, we transiently depleted ZEB1 with siRNA (siZEB1) in DRD2-overexpressing SW480 cells. As shown in Figure 5E, siZEB1 reduced vimentin protein levels, but markedly enhanced E-cadherin levels in DRD2-overexpressing SW480 cells. Additionally, we confirmed that the β-catenin/ZEB1 axis could affect DRD2-mediated CRC cell growth (Figure 5F). Collectively, these results showed that overexpressing DRD2 activated the β-catenin pathway, which may enhance ZEB1 expression and thereby promote CRC progression.

### 3.6 | Pimozide decreases CRC tumor growth and motility in vitro and in vivo

To determine whether the DRD2 antagonist pimozide inhibits DRD2 and its associated proteins, we treated HCT116 cells with pimozide. Pimozide significantly reduced DRD2, ZEB1, β-catenin, and vimentin expression (Figure 6A). In addition, pimozide enhanced the cytotoxicity of conventional agents 5FU and oxaliplatin in CRC cells (Figure 6B). In cell cycle analysis, combined treatment caused G2/M phase arrest, leading to increasing apoptotic cells (sub-G1 phase) compared with any single treatment (Figure 6C). The migratory ability was also inhibited by combined treatment compared with single treatment (Figure 6D).

To explore whether pimozide induced an anti-tumor effect in vivo, HCT116 cells were subcutaneously injected into mice. Mice were treated with vehicle saline or pimozide at 25 mg/kg twice weekly by intraperitoneal injection, and tumor volume was measured twice weekly. Pimozide effectively suppressed increases in tumor volume and weight compared with the control group (Figure 7A-C). IHC staining revealed that pimozide decreased not only DRD2 but also β-catenin and ZEB1 expression compared with the control group (Figure 7D). Furthermore, lymph nodes from pimozide-treated mice showed fewer pan-cytokeratin-positive tumor cells than those from untreated mice, indicating that pimozide effectively suppressed tumor cell infiltration into lymph nodes (Figure 7E). These results showed that inhibition of DRD2 by pimozide induced an anti-tumor effect in CRC.
DISCUSSION

We found that elevated DRD2 expression was positively correlated with high-grade CRC in patients. We also demonstrated that DRD2 promoted CRC growth and motility in vitro and in vivo through the activation of β-catenin/ZEB1 signaling. Moreover, the DRD2 antagonist pimozide reduced tumor growth and metastasis, pointing toward DRD2 inhibition as a potential therapeutic strategy for CRC.

Several reports have indicated that altered expression of DRs is involved not only in neurological disorders but also in tumor progression. A previous study by Kline and colleagues showed that DRD2 mRNA expression is highly variable across different cancers from large-scale cancer genomics datasets. Other studies suggested that DRD2 expression can be used to evaluate the prognosis of patients with gastric or esophageal cancer. Experimental studies also reported that DRD2 knockdown was sufficient to inhibit cell viability in pancreatic cancer and glioblastoma cells. Consistent with these findings, we showed that mRNA levels of all DRs were higher in tumor tissue derived from patients with CRC compared with the corresponding non-tumor tissue, in particular DRD2 expression was higher than that of other DR subfamilies. In addition, we found that DRD2 expression was positively correlated with poor prognosis of patients with CRC. However, no previous studies provided experimental evidence of how DRD2 functions in cell growth and motility in CRC.

DRD2 antagonists, such as trifluoperazine, haloperidol, pimozide, and thioridazine, are approved by the FDA as antipsychotic agents. Interestingly, schizophrenic patients treated with DRD2 antagonists have a decreased rate of occurrence of various solid tumors, including...
CRC and prostate cancer, compared with the general population. In accordance with this observation, reduced cancer incidence rates have been reported for patients with Parkinson’s disease, in which the dopaminergic pathway is deficient. A previous study showed that a DRD2 antagonist inhibited the PI3K/AKT pathway in cancer stem cells, leading to blockade of cell cycle progression and migration via decreased expression of stem and motility-related genes in vitro. In addition, pimozide increases apoptosis and represses migration by inhibiting MMP2 expression in melanoma cells. DRD2 deficiency triggers the activation of endoplasmic reticulum stress, which leads to cell death. Although previous studies have reported that DRD2 antagonists induce an anti-proliferative effect in various cancer cells, the precise molecular mechanisms underlying DRD2-mediated CRC migration, invasion, and metastasis are not well known. Therefore, in this study, we targeted DRD2 using stable DRD2 knockdown to investigate DRD2-induced signaling pathways contributing to CRC progression.

A recent study showed that DRD2 regulates cell proliferation through the Wnt/β-catenin pathway, which enhances the transcriptional activity of Wnt3a. DRD2 antagonists reduce phosphorylation of β-catenin and AKT, leading to blocked migration of cancer cells. In GPCR-dependent signaling, β-arrestins facilitate receptor internalization and stimulate downstream targets such as AKT, GSK3β, and Wnt/β-catenin signaling. β-Catenin...
is a critical regulator and transducer of GPCRs, which play roles in various physiological and pathological processes in cancer growth.\(^4^0\) Moreover, β-catenin also plays a critical role in promoting EMT by regulating the expression of EMT-related transcription factors.\(^4^1,4^2\) It has been reported that phosphorylation of β-catenin at Ser552 promotes transcriptional activity and tumor cells invasion.\(^4^3\) In addition, phosphorylation of β-catenin at Ser675 suppresses its ubiquitination and further accumulation of β-catenin in the nucleus.\(^4^4\) Therefore, activated Wnt/β-catenin signaling may contribute to the proliferation and motility of cancer cells, thereby promoting tumorigenesis.

Here, we hypothesized that DRD2 regulated EMT-associated genes through Wnt/β-catenin in CRC. We examined 2 different regions of DRD2 mRNA constructs that impaired proliferation and motility of HCT116 cells (Figure S2). Among these, we selected the most effective shRNA to inhibit cell proliferation. We found that depletion of DRD2 significantly downregulated ZEB1 mRNA expression compared with other EMT transcription factors. In addition, knockdown of DRD2 reduced β-arrestin1/2 and its downstream proteins, including β-catenin, ZEB1, AKT, and GSK3β, whereas overexpression of DRD2 increased β-catenin and its associated proteins. We also confirmed that phosphorylation of β-catenin was regulated according to the level of DRD2 expression. These results are consistent with a previous report that ZEB1 is a direct target of β-catenin/TCF4 in CRC.\(^4^5\) Additionally, our patient-derived CRC tissue array data showed that high DRD2 expression was positively correlated with high levels of β-catenin and ZEB1. We also found that pimozide reduced cell viability and motility by suppressing the β-catenin/ZEB1 signaling pathway in CRC. These results suggested that overexpression of DRD2 enhanced CRC cell metastatic ability and promoted EMT through the activation of the transcription factor ZEB1, suggesting that inhibition of DRD2 could enhance therapeutic efficacy in patients with CRC.

In summary, DRD2 was significantly upregulated in high-grade CRC and associated with a poor survival rate. Depletion of DRD2 led to suppression of proliferative, migratory, and invasive abilities via downregulation of β-catenin/ZEB1 signaling in CRC both in vitro and in vivo. Similarly, treatment with the DRD2 antagonist pimozide enhanced the anti-tumor activity of conventional agents for CRC in vitro and in vivo. These findings suggest that DRD2 could serve as a prognostic marker and that targeting DRD2 may be therapeutically beneficial for patients with CRC.

**DISCLOSURE**

The authors have no conflicts of interest to report.

**ORCID**

Hyunjung Lee \(\text{https://orcid.org/0000-0002-1111-9061}\)

Aureumnuri Kim \(\text{https://orcid.org/0000-0002-3133-8974}\)

**REFERENCES**

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.

2. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst. 2009;101:1308-1324.

3. Seiwert TY, Salama JK, Vokes EE. The concurrent chemoradiation paradigm—general principles. Nat Clin Pract Oncol. 2007;4:86-100.

4. Qin S, Zhou Y, Chen J, et al. Low levels of TSC22 enhance tumorigenesis by inducing cell proliferation in colorectal cancer. Biochem Biophys Res Commun. 2018;497:1062-1067.

5. Lourenço FC, Munro J, Brown J, et al. Reduced LIMK2 expression in colorectal cancer reflects its role in limiting stem cell proliferation. Gut. 2014;63:480-493.

6. Urbanska AM, Karagiannis ED, Guajardo G, Langer RS, Anderson DG. Therapeutic effect of orally administered microencapsulated oxaliplatin for colorectal cancer. Biomaterials. 2012;33:4752-4761.

7. Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat Rev Mol Cell Biol. 2002;3:639-650.

8. Dolma S, Selvadurai HJ, Lan X, et al. Inhibition of dopamine receptor D4 impedes autophagic flux, proliferation, and survival of glioblastoma stem cells. Cancer Cell. 2016;29:859-873.

9. Figueroa C, Gálvez-Cancino F, Oyarce C, et al. Inhibition of dopamine receptor D3 signaling in dendritic cells increases antigen cross-presentation to CD8(+) T-cells favoring anti-tumor immunity. J Neuroimmunol. 2017;303:99-107.

10. Borchertding DC, Tong W, Hugo ER, et al. Expression and therapeutic targeting of dopamine receptor-1 (D1R) in breast cancer. Oncogene. 2016;35:3103-3113.

11. Lu M, Li J, Luo Z, et al. Roles of dopamine receptors and their antagonists thioreidazone in hepatoma metastasis. Onco Targets Ther. 2015;8:1543-1552.

12. Song Q, Ji Q, Li Q. The role and mechanism of β-arrestins in cancer invasion and metastasis (Review). Int J Mol Med. 2018;41:631-639.

13. Frank B, Hoffmeister M, Klopp N, Iill T, Chang-Claude J, Brenner H. Single nucleotide polymorphisms in Wnt signaling and cell death pathway genes and susceptibility to colorectal cancer. Carcinogenesis. 2010;31:1381-1386.

14. Liu C, Li Y, Semenov M, et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell. 2002;108:837-847.

15. Polakis P, Hart M, Rubinfeld B. Defects in the regulation of beta-catenin in colorectal cancer. Adv Exp Med Biol. 1999;470:23-32.

16. Baldus SE, Möning SP, Huxel S, et al. MUC1 and nuclear β-catenin are coexpressed at the invasion front of colorectal carcinomas and are both correlated with tumor prognosis. Clin Cancer Res. 2004;10:2790-2796.

17. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330-337.

18. Pai P, Raghani S, Dhawan P, Batra SK. Mucins and Wnt/β-catenin signaling in gastrointestinal cancers: an unholy nexus. Carcinogenesis. 2016;37:223-232.

19. Tsai JH, Yang J. Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev. 2013;27:2192-2206.

20. Jiang H, Cao HJ, Ma N, et al. Chromatin remodeling factor ARID2 suppresses hepatocellular carcinoma metastasis via DNMT1-Snail axis. Proc Natl Acad Sci U S A. 2020;117:4770-4780.

21. Krebs AM, Mitschke J, Lasieria Losada M, et al. The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nat Cell Biol. 2017;19:518-529.

22. Cano A, Pérez-Moreno MA, Rodrigo I, et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol. 2000;2:76-83.

23. Cao J, Wang X, Dai T, et al. Twist promotes tumor metastasis in basal-like breast cancer by transcriptionally upregulating ROR1. Theranostics. 2018;8:2739-2751.
24. Osinga TE, Links TP, Dullaart RPF, et al. Emerging role of dopamine in neovascularization of pheochromocytoma and paraganglioma. *Faseb J*. 2017;31:2226-2240.

25. Shevtsov SP, Haq S, Force T. Activation of beta-catenin signaling pathways by classical G-protein-coupled receptors: mechanisms and consequences in cycling and non-cycling cells. *Cell Cycle*. 2006;5:2295-2300.

26. Zhang C, Gong P, Liu P, Zhou N, Zhou Y, Wang Y. Thioridazine elicits potent antitumor effects in colorectal cancer stem cells. *Oncol Rep*. 2017;37:1168-1174.

27. Zhang X, Liu Q, Liao Q, Zhao Y. Potential roles of peripheral dopamine in tumor immunity. *J Cancer*. 2017;8:2966-2973.

28. Kline CLB, Ralff MD, Lulla AR, et al. Role of dopamine receptors in the anticancer activity of ONC201. *Neoplasia*. 2018;20:80-91.

29. Li J, Zhu S, Kozono D, et al. Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma. *Oncotarget*. 2014;5:882-893.

30. Jandaghi P, Najafabadi HS, Bauer AS, et al. Expression of G protein-coupled GPCRs in human pancreatic ductal adenocarcinoma and inhibitors slow tumor growth: a mouse model. *Gastroenterology*. 2016;151:1218-1231.

31. Jia H, Ren W, Fong Y, et al. The enhanced antitumour response of pimozide combined with the IDO inhibitor L-MT in melanoma. *Int J Oncol*. 2018;53:949-960.

32. Tinsley RB, Bye CR, Parish CL, et al. Dopamine D2 receptor knockout mice develop features of Parkinson disease. *Ann Neurol*. 2009;66:472-484.

33. Clarke HJ, Chambers JE, Liniker E, Marciñak SJ. Endoplasmic reticulum stress in malignancy. *Cancer Cell*. 2014;25:563-573.

34. Han F, Konkalmatt P, Mokashi C, et al. Dopamine D(2) receptor modulates Wnt expression and control of cell proliferation. *Sci Rep*. 2019;9:16861.

35. Palacios-Gross A, Li J, Zheng C, et al. Repurposing the antipsychotic trifluperazine as an antimitostasis agent. *Mol Pharmacol*. 2015;87:501-512.

36. Nag JK, Rudina T, Maoz M, Grisaru-Granovsky S, Uziely B, Bar-Shavit R. Cancer driver G-protein-coupled receptor (GPCR) induced beta-catenin nuclear localization: the transcriptional junction. *Cancer Metastasis Rev*. 2018;37:147-157.

37. Zhai H, Ren W, Fong Y, et al. The enhanced antitumour response of pimozide combined with the IDO inhibitor L-MT in melanoma. *Int J Oncol*. 2018;53:949-960.

38. Han F, Konkalmatt P, Mokashi C, et al. Dopamine D(2) receptor modulates Wnt expression and control of cell proliferation. *Sci Rep*. 2019;9:16861.

39. Palacios-Gross A, Li J, Zheng C, et al. Repurposing the antipsychotic trifluperazine as an antimitostasis agent. *Mol Pharmacol*. 2015;87:501-512.

40. Nag JK, Rudina T, Maoz M, Grisaru-Granovsky S, Uziely B, Bar-Shavit R. Cancer driver G-protein-coupled receptor (GPCR) induced beta-catenin nuclear localization: the transcriptional junction. *Cancer Metastasis Rev*. 2018;37:147-157.

41. Zhai H, Ren W, Fong Y, et al. The enhanced antitumour response of pimozide combined with the IDO inhibitor L-MT in melanoma. *Int J Oncol*. 2018;53:949-960.